Skinvisible provides update on ongoing trials conducted by Quoin

Skinvisible (SKVI) shared an update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals (QNRX). The trials focus on the innovative formulation “QRX003,” powered by Skinvisible’s Invisicare proprietary drug delivery technology, to address the challenges of Netherton Syndrome. Netherton Syndrome is a hereditary disorder affecting the skin, hair and immune system, currently lacking an approved treatment or cure. The preliminary results and updates from Quoin’s ongoing clinical studies, operating under an open Investigational New Drug application, indicate noteworthy progress: Positive Initial Data and Clean Safety Profile: The trials have demonstrated positive initial data and a clean safety profile, leading to the implementation of an optimization plan. Optimization Plan Implementation: Quoin has increased the size of both clinical trials significantly and adjusted dosing frequency to twice-daily from once-daily for both trials. Elimination of Lower Dose: In the blinded trial, a lower dose has been eliminated based on the positive outcomes observed. Protocol Amendments: Quoin’s press release highlights protocol amendments aimed at enhancing the data set and potentially expediting regulatory approval. The Company previously announced that QRX003, the first Invisicare delivery technology product, has already received acceptance for an Investigational New Drug Application from the U.S. Food and Drug Administration. Quoin is actively working towards obtaining necessary FDA and other regulatory approvals for marketing the product in the United States and other countries.